A better understanding of how the measurement of PD-L1 expression in EBUS-TBNA specimens affected the subsequent design of personalized cancer therapies would have been helpful and could have been compared to a previous study that demonstrated that patients whose EBUS-TBNA samples reflected higher PD-L1 expression had near complete treatment response after ICI initiation [16]. This evidence concerns the gene CD274 and cancer.